Managing Dravet syndrome requires a multidisciplinary approach open to both pharmacological and non-pharmacological treatments, because of the severe nature of…
Articles by Joana Carvalho, PhD
Diacomit (stiripentol) is an effective add-on oral therapy to reduce the frequency and duration of seizures…
A genetic phenomenon called double somatic mosaicism was found for a first time in a girl with Dravet syndrome, a…
The anti-seizure effect of cannabidiol in Dravet syndrome is dependent on the type of neurons upon which it…
Potassium bromide (KBr) can control certain types of epileptic seizures and should be considered as an option for…
Scientists have found a new genetic mutation in the SCN1A gene associated with Dravet syndrome, a case report…
Treatment with AZD7325, a compound that stimulates the activity of a specific type of receptors in the brain,…
GW Pharmaceuticals‘ Epidiolex, the first plant-derived cannabidiol (CBD) medication to be approved by the…
Compared with its competitors, Diacomit (stiripentol) remains in the top position as an add-on therapy to control epileptic…
The U.S. Food and Drug Administration (FDA) refused the New Drug Application (NDA) for Fintepla (ZX008),…